- Home
- MXCT vs PRQR Comparison
MXCT vs PRQR Comparison
Compare MXCT & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MXCT | PRQR |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.7M | 250.7M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MXCT | PRQR |
|---|---|---|
| Price | $1.51 | $2.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $7.50 | ★ $8.14 |
| AVG Volume (30 Days) | ★ 1.6M | 540.5K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $34,419,000.00 | $18,859,556.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.69 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.26 | $1.07 |
| 52 Week High | $5.20 | $3.46 |
Technical Indicators
Market Signals| Indicator | MXCT | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 44.35 | 53.75 |
| Support Level | $1.50 | $2.15 |
| Resistance Level | $1.65 | $2.42 |
| Average True Range (ATR) | 0.11 | 0.19 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 22.37 | 79.70 |
Price Performance
Historical ComparisonAbout MXCT MaxCyte Inc.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.